Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002357 · ClinicalTrials.gov registry record · Phase 2
The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms
A Phase 2 study, sponsored by Hoechst Marion Roussel.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
NCT00002357: Completed Phase 2 study, sponsored by Hoechst Marion Roussel.
NCT00002357 is a Phase 2 study that has completed, run by Hoechst Marion Roussel. The registered enrollment target is 144 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002357, a Phase 2 study, has completed, sponsored by Hoechst Marion Roussel.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
Study Summary
To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone. PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.
Interventions
- DRUG Zidovudine
- DRUG HBY 097
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Phase | Phase 2 |
What the finished NCT00002357 record still lists
NCT00002357 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Zidovudine is the first listed.
NCT00002357 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002357 about?
NCT00002357 is a clinical study titled "The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms". To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone. PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.
What is the current status of trial NCT00002357?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants.
What interventions are being tested in trial NCT00002357?
The interventions under investigation include: Zidovudine (DRUG), HBY 097 (DRUG).
Who is sponsoring clinical trial NCT00002357?
This trial is sponsored by Hoechst Marion Roussel, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002357's enrollment target sits among peer trials
144 500th of 2000 higher than 1,494 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS